Metagenomi to Present at Upcoming Scientific Meetings
Metagenomi to Present at Upcoming Scientific Meetings
- Oral Presentation at World Federation of Hemophilia (WFH) World Congress, April 23, 2024
-在世界血友病聯合會(WFH)世界大會上的口頭陳述, 2024年4月23日
- Two Posters at American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, May 8 & 9, 2024
-2024 年 5 月 8 日和 9 日美國基因與細胞療法學會 (ASGCT) 2024 年年會上的兩張海報
EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced that the Company will present at two upcoming scientific meetings: a late breaking oral presentation at The World Federation of Hemophilia (WFH) World Congress, taking place April 21 – 24, 2024 in Madrid, Spain and two poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.
加利福尼亞州埃默裏維爾,2024年4月8日(GLOBE NEWSWIRE)——致力於使用其專有的綜合宏基因組學衍生基因編輯工具箱爲患者開發治療藥物的精準基因醫學公司Megenomi, Inc.(納斯達克股票代碼:MGX)今天宣佈,該公司將出席即將舉行的兩次科學會議:在世界血友病聯合會(WFH)世界大會上的最新口頭演講,將於 2024 年 4 月 21 日至 24 日在西班牙馬德里舉行,並在美國基因與細胞療法學會舉辦了兩場海報發佈會(ASGCT) 2024 年年會將於 2024 年 5 月 7 日至 11 日在馬里蘭州巴爾的摩以虛擬方式舉行。
WFH 2024 World Congress
Madrid, Spain
April 21-24, 2024
WFH 2024 世界大會
西班牙馬德里
2024 年 4 月 21 日至 24 日
Oral Presentation Title: Metagenomi:
Potentially Curative Gene Editing Approach for Hemophilia A
Session: Late breaking session: New tech
Location: N103+N104
Date / time: Tuesday, April 23, 2024, 16:00 – 17:00 CEST
口頭演講題目:宏基因學:
A型血友病的潛在治療基因編輯方法
會議:後期會議:新技術
地點:N103+N104
日期/時間:2024 年 4 月 23 日,星期二,歐洲中部標準時間 16:00 — 17:00
ASGCT 2024 Annual Meeting
Baltimore, MD
May 7-9, 2024
ASGCT 2024 年年會
馬里蘭州巴爾的摩
2024 年 5 月 7 日至 9 日
Poster Title: Novel CRISPR Effectors and Reverse Transcriptases Discovered from Metagenomics Enable Extensive Remodeling of the Human Genome
Abstract Number: 1209
Location: Exhibit Hall
Date / time: Thursday, May 9, 2024, 12:00 p.m. ET
海報標題:從宏基因組學中發現的新型 CRISPR 效應器和逆轉錄酶可實現對人類基因組的廣泛重塑
摘要編號:1209
地點:展廳
日期/時間:美國東部時間 2024 年 5 月 9 日星期四下午 12:00
Poster Title: Novel and Efficient Base Editors Engineered to Comprehensively Target the Human Genome
Abstract Number: 684
Location: Exhibit Hall
Date / time: Wednesday, May 8, 2024, 12:00 p.m. ET
海報標題:專爲全面靶向人類基因組而設計的新穎高效鹼基編輯器
摘要編號:684
地點:展廳
日期/時間:美國東部時間 2024 年 5 月 8 日星期三下午 12:00
All presentations will be made available on the "News & Events," page in the Investors section of the Company's website at
所有演示文稿將在公司網站 “投資者” 部分的 “新聞與活動” 頁面上公佈
About Metagenomi
關於 Megenomi
Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived toolbox. Metagenomi is harnessing the power of metagenomics, the study of genetic material recovered from the natural environment, to unlock four billion years of microbial evolution to discover and develop a suite of novel editing tools capable of correcting any type of genetic mutation found anywhere in the genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases). Metagenomi believes its diverse and modular toolbox positions the company to access the entire genome and select the optimal tool to unlock the full potential of genome editing for patients. For more information, please visit https://metagenomi.co.
Megenomi是一家精準基因藥物公司,致力於使用其專有的綜合宏基因組學衍生工具箱爲患者開發治療性療法。Megenomi正在利用宏基因組學(研究從自然環境中回收的遺傳物質)的力量來解鎖40億年的微生物進化,以發現和開發一套新穎的編輯工具,能夠糾正基因組中任何地方發現的任何類型的基因突變。其全面的基因組編輯工具箱包括可編程核酸酶、鹼基編輯器以及RNA和DNA介導的整合系統(包括主要編輯系統和聚類的定期間隔的短迴文重複相關轉座酶)。Metagenomi認爲,其多樣化的模塊化工具箱使公司能夠訪問整個基因組,並選擇最佳工具來釋放患者基因組編輯的全部潛力。欲了解更多信息,請訪問 https://metagenomi.co。
Cautionary Note Regarding Forward‐Looking Statements
關於前瞻性陳述的警示說明
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions, include, but are not limited to, any statements relating to our growth strategy and product development programs, including the timing of and our ability to conduct IND-enabling studies, make regulatory filings such as INDs and other applications and to obtain regulatory approvals for our product candidates, statements concerning the potential of therapies and product candidates, and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in "Risk Factors," in our most recent Form 10-K, on file with the SEC. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
本新聞稿包含1933年《證券法》第27A條和1934年《證券交易法》第21E條所指的 “前瞻性陳述”,均經修訂。此類陳述通常用 “預測”、“相信”、“可能”、“估計”、“預期”、“目標”、“打算”、“展望”、“可能”、“計劃”、“潛力”、“預測”、“項目”、“應該”、“將” 和類似的表述來表示,包括但不限於與我們的增長戰略相關的任何陳述以及產品開發計劃,包括開展支持IND的研究、提交IND和其他申請等監管文件以及獲得監管的時機和我們的能力對我們候選產品的批准、有關療法和候選產品潛力的陳述,以及任何其他非歷史事實的陳述。前瞻性陳述基於管理層當前的預期,受風險和不確定性的影響,這些風險和不確定性可能會對我們的業務、經營業績、財務狀況和股票價值產生負面影響。可能導致實際結果與當前預期結果存在重大差異的因素包括:與我們的增長戰略相關的風險;我們獲得、履行和維持融資和戰略協議及關係的能力;與研發活動結果相關的風險;與開始和完成臨床試驗的時間相關的風險;與臨床前和臨床測試相關的不確定性;我們對第三方供應商的依賴;我們的吸引能力培養和留住關鍵人員;在開發產品的早期階段;我們對大量額外資金的需求;政府監管;專利和知識產權事務;競爭;以及我們向美國證券交易委員會提交的最新10-K表中 “風險因素” 中描述的其他風險。除非法律要求,否則我們明確表示不承擔任何義務或承諾公開發布此處包含的任何前瞻性陳述的任何更新或修訂,以反映我們預期的任何變化或任何此類陳述所依據的事件、條件或情況的任何變化,並且我們要求1995年《私人證券訴訟改革法》中包含的前瞻性陳述受到安全港的保護。
Investor Contact:
Simon Harnest CIO, SVP Investor Relations
simon@metagenomi.co
投資者聯繫方式:
西蒙·哈內斯特首席信息官、投資者關係高級副總裁
simon@metagenomi.co
Media Contact:
Ashlye Hodge, Communications Manager
ashlye@metagenomi.co
媒體聯繫人:
Ashlye Hodge,傳播經理
ashlye@metagenomi.co